Upstream solutions for price-gouging on critical generic medicines

Journal of Pharmaceutical Policy and Practice

Reed F. Beall¹  Amir Attaran¹  Adam R. Houston¹ 

[1] University of Ottawa, Room 221 1 Stewart St, Ottawa, ON K1N 6N5 Canada

关键词: Essential medicines;    Generics trolling;    Cycloserine;    Pyrimethamine;    Pharmaceutical pricing;    Generic drugs;   

DOI  :  10.1186/s40545-016-0064-8

学科分类：药理学

来源: BioMed Central

【 摘 要 】

Exorbitant price increases for critical off-patent medicines have received considerable media attention in recent months, leading to an investigation by the U.S. Senate. However, much of this attention has focused upon the companies that initiated the price increases, all of whom had recently acquired the drugs in question. Overlooked are upstream interventions with the originators of these drugs to prevent generics trolling in the first place. Using the particular example of Eli Lilly and Company’s efforts to divest itself of cycloserine, a flawed process that paved the way for the recent price hike by Rodelis Therapeutics, this article highlights the responsibilities of drug originators, and safeguards to ensure similar rights transfers do not affect ongoing affordable access.

【 授权许可】

Unknown